The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer by Dai, Fuqiang et al.
Dai et al. BMC Cancer 2010, 10:220
http://www.biomedcentral.com/1471-2407/10/220
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Dai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article The number and microlocalization of 
tumor-associated immune cells are associated with 
patient's survival time in non-small cell lung cancer
Fuqiang Dai1,2, Lunxu Liu*1, Guowei Che1, Nanbin Yu1,3, Qiang Pu1, Shangfu Zhang1, Junliang Ma1, Lin Ma1 and 
Zongbing You*4
Abstract
Background: Tumor microenvironment is composed of tumor cells, fibroblasts, endothelial cells, and infiltrating 
immune cells. Tumor-associated immune cells may inhibit or promote tumor growth and progression. This study was 
conducted to determine whether the number and microlocalization of macrophages, mature dendritic cells and 
cytotoxic T cells in non-small cell lung cancer are associated with patient's survival time.
Methods: Ninety-nine patients with non-small cell lung cancer (NSCLC) were included in this retrospective study. 
Paraffin-embedded NSCLC specimens and their clinicopathological data including up to 8-year follow-up information 
were used. Immunohistochemical staining for CD68 (marker for macrophages), CD83 (marker for mature dendritic 
cells), and CD8 (marker for cytotoxic T cells) was performed and evaluated in a blinded fashion. The numbers of 
immune cells in tumor islets and stroma, tumor islets, or tumor stroma were counted under a microscope. Correlation 
of the cell numbers and patient's survival time was analyzed using the Statistical Package for the Social Sciences 
(version 13.0).
Results: The numbers of macrophages, mature dendritic cells and cytotoxic T cells were significantly more in the 
tumor stroma than in the tumor islets. The number of macrophages in the tumor islets was positively associated with 
patient's survival time, whereas the number of macrophages in the tumor stroma was negatively associated with 
patient's survival time in both univariate and multivariate analyses. The number of mature dendritic cells in the tumor 
islets and stroma, tumor islets only, or tumor stroma only was positively associated with patient's survival time in a 
univariate analysis but not in a multivariate analysis. The number of cytotoxic T cells in the tumor islets and stroma was 
positively associated with patient's survival time in a univariate analysis but not in a multivariate analysis. The number 
of cytotoxic T cells in the tumor islets only or stroma only was not associated with patient's survival time.
Conclusions: The number of macrophages in the tumor islets or stroma is an independent predictor of survival time in 
NSCLC patients. Counting macrophages in the tumor islets or stroma is more useful in predicting patient's survival time 
than counting mature dendritic cells or cytotoxic T cells.
Background
Tumor microenvironment is composed of tumor cells,
resident cells such as fibroblasts and endothelial cells, and
infiltrating cells such as macrophages, dendritic cells, and
lymphocytes, as well as products of all these cells such as
extracellular matrix, growth factors, cytokines, chemok-
ines, enzymes, and various metabolites [1]. The cross-
talk between tumor cells and other tumor-associated cells
may lead to either blocking tumor formation or enhanc-
ing tumor formation and/or progression. The double-
edged-sword nature of many tumor-associated immune
cells such as macrophages, dendritic cells, and cytotoxic
T cells has been recognized [2-4]. On the one hand, these
immune cells may recognize tumor-associated antigen
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and activate cytotoxic T cells, in order to initiate anti-
tumor immune responses. On the other hand, the same
immune cells may establish immune tolerance and even
promote tumor growth and metastasis through enhanc-
ing angiogenesis and invasion of extracellular matrix.
Non-small cell lung cancer (NSCLC) is the most com-
mon cause of cancer-related death worldwide. The five-
year survival rate is approximately 67% for the patients
with stage IA NSCLC after putatively curative surgery [5].
In order to identify new prognostic factors that can guide
clinical practice, we have previously found that the num-
ber of tumor-associated macrophages (TAMs) in the
tumor islets is positively associated with survival time in
the patients with NSCLC [6]. Because TAMs are not the
only tumor-associated immune cells, in this study we fur-
ther investigated the prognostic value of mature dendritic
cells and cytotoxic T cells in the patients with NSCLC.
Methods
Study population
This study was approved by the Institutional Review
Board of West China Hospital, Sichuan University. The
procedures to obtain human lung cancer tissues and fol-
low-up information are in accordance with the Ethical
Principles for Medical Research Involving Human Sub-
jects as formulated in the World Medical Association
Declaration of Helsinki (revised in 2008). All specimens
were obtained from the archives of formalin-fixed, paraf-
fin-embedded tissue blocks in the Department of Tho-
racic and Cardiovascular Surgery, West China Hospital,
Sichuan University. The lung cancer tissues were col-
lected from surgeries performed from August, 1999 to
August, 2001. The patients were followed up until
December, 2007, through outpatient visits and/or corre-
spondences to family members. Ninety-nine patients
were included in this retrospective study. Histological
evaluation was based on the World Health Organization
criteria [7]. Tumor stage was evaluated according to the
International Union against Cancer TNM classification
system [7]. The clinicopathological characteristics were
summarized in Table 1.
Immunohistochemistry
Four-μm thick tissue sections were de-waxed in xylene
and rehydrated through graded alcohols. Antigen
retrieval was carried out using microwave at middle-to-
high temperature for 8 min, low-to-high temperature for
5 min, and then cooled down at room temperature for 20
min. Mouse anti-human CD68 monoclonal antibodies
(clone KP1, recognizing macrophages), rabbit anti-
human CD8 monoclonal antibodies (clone SP16, recog-
nizing cytotoxic T cells), and streptavidin-peroxidase
conjugated secondary antibodies (SP-9002) were
obtained from Zhongshan Goldenbridge Biotechnology
Co., LTD., Beijing, China. Mouse anti-human CD83
monoclonal antibodies (clone HB15a, recognizing
mature dendritic cells) were obtained from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA. Diaminobenz-
idine (DAB) substrate kit was obtained from Dako North
America, Inc., Carpinteria, CA, USA. Immunohis-
tochemical staining of individual markers was performed
according to the kit manufacturer's instructions. Sections
were then counterstained with hematoxylin and mounted
in an aqueous mounting medium. Tissue sections previ-
ously stained positively were used as positive control,
while tissue sections with primary antibodies replaced by
phosphate-buffered saline served as negative control.
Positive cells showed brown particles on the cellular
membrane and/or in the cytoplasm. Under a microscope,
five representative high-power fields (× 400 magnifica-
tion) of the tumor islets and stroma per tissue section
were selected and counted for positive cell numbers. The
average number of these five high-power fields repre-
sented the cell number per high-power field. Evaluation
of the stained tissue sections was performed by two
investigators who were blinded in regard to the clinico-
pathological characteristics. An average of the results
obtained by the two examiners was used to represent
each case.
Statistical analysis
Statistical analysis was carried out using the Statistical
Package for the Social Sciences (SPSS, version 13.0, SPSS
Inc., Chicago, IL, USA). For categorical analysis, the
median number of cells per high-power field was used as
a cut-off point to dichotomize the continuous variables.
The Mann-Whitney nonparametric test was used to
compare between two groups. In order to assess any
potential relationship between the number of immune
cells and patient's survival time, the Spearman's rank cor-
relation coefficient (Spearman's rho, or rs) was calculated
in a univariate analysis. The correlation between the
number of immune cells and the clinicopathological
characteristics was analyzed using the χ2  test. The
Kaplan-Meier survival curves were used to look for cor-
relation between the cell number and patient's survival
time, or between the ratio of cells in the tumor islets ver-
sus stroma and patient's survival time. Statistical signifi-
cance was analyzed using the log-rank test. A
multivariate Cox proportional hazards model was used to
estimate adjusted hazard ratios and 95% confidence inter-
vals (CI) and to identify which variable was an indepen-
dent prognostic factor. The validity of the proportional
hazards assumption was assessed from log (-log [Sur-
vival]) curves. For the above comparisons, P < 0.05 was
considered statistically significant.Dai et al. BMC Cancer 2010, 10:220
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Results
Patient characteristics
All of the 99 patients (Table 1) had complete follow-up
information and the pathological diagnosis was verified
by a pathologist prior to inclusion in this study. The over-
all cumulative 5-year survival rate was 32%. Patients with
stage I carcinomas, squamous cell carcinomas, well-dif-
ferentiated carcinomas, or carcinomas without lymph
node metastasis had better survival rates than the other
patients (Table 1).
Immunohistochemical detection of the tumor-associated 
immune cells
Macrophages, mature dendritic cells, and cytotoxic T
cells were detected by anti-CD68 antibodies, anti-CD83
antibodies, and anti-CD8 antibodies, respectively (Figure
1). These tumor-associated immune cells were located in
both the tumor islets and stroma. Under each high-power
field (× 400 magnification), the median number of mac-
rophages in the tumor islets and stroma is approximately
15 (Table 2). The median number of macrophages in the
tumor islets only is approximately 4. The median number
of macrophages in the tumor stroma only is approxi-
mately 7, which was significantly more than that in the
tumor islets (P = 0.040). The median numbers of mature
dendritic cells in the tumor islets and stroma, tumor islets
only, or tumor stroma only were approximately 13, 4, or 7,
respectively (Table 2). The number of mature dendritic
cells in the tumor stroma was significantly more than that
in the tumor islets (P = 0.000). The median numbers of
CD8+ cytotoxic T cells in the tumor islets and stroma,
tumor islets only, or tumor stroma only were approxi-
mately 11, 4, or 7, respectively (Table 2). The number of
Table 1: Clinicopathological characteristics of patients with non-small cell lung cancer (n = 99)
Variable N = 99 5-yr survival (%)
Age years median (range) 60 ( 37 - 80) Overall
Gender (male: female) 80:19 32
Tumor stage:
I3 5 4 9
II 20 35
III 34 19
IV 10 10
Histology
Adenocarcinoma 45 22
Squamous cell carcinoma 51 41
Large cell carcinoma 3 33
Tumor grade
Well differentiation 3 67
Moderate differentiation 48 40
Poor differentiation 29 24
Not recorded 19 20
Lymph node metastasis
No 59 44
Yes 40 15
Histological criteria for the tumor grading:
Adenocarcinomas:
Well differentiation: glandular lumens are large and similar in sizes, with less cytologic atypia.
Moderate differentiation: glandular lumens vary in sizes, with obvious cytologic atypia.
Poor differentiation: glandular lumens are small or absent, with obvious cytologic atypia and mitosis.
Squamous cell carcinomas:
Well differentiation: ≥ 20% of the tumor islets has pearl formation.
Moderate differentiation: < 20% of the tumor islets has pearl formation.
Poor differentiation: no pearl formation in the tumor islets; only shows intracellular keratinization.
Large cell carcinomas: by definition, are poorly differentiated tumors that lack the cytologic and architectural features of small cell carcinoma, 
squamous cell carcinoma, or adenocarcinoma.Dai et al. BMC Cancer 2010, 10:220
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CD8+ cytotoxic T cells in the tumor stroma was signifi-
cantly more than that in the tumor islets (P = 0.032).
Correlation between the number and microlocalization of 
immune cells and survival time
The Spearman's rank correlation coefficient (Spearman's
rho, or rs) was calculated to assess any potential relation-
ship between the tumor-associated immune cells and
patient's survival time. We found that the macrophage
number in the tumor islets and stroma had no association
with patient's survival time (rs = -0.105, P = 0.300). The
macrophage number in the tumor islets was positively
associated with patient's survival (rs = 0.483, P = 0.000). In
contrast, the macrophage number in the tumor stroma
was negatively associated with patient's survival (rs = -
0.541, P = 0.000) (Table 2). The numbers of mature den-
dritic cells in the tumor islets and stroma, tumor islets,
and tumor stroma were all positively associated with
patient's survival time, with rs = 0.221 (P = 0.028), 0.404
(P = 0.001), and 0.284 (P = 0.045), respectively. Similarly,
the numbers of CD8+ cytotoxic T cells in the tumor islets
and stroma, tumor islets, and tumor stroma were also
positively associated with patient's survival time, with rs =
0.297 (P = 0.003), 0.247 (P = 0.014), and 0.212 (P = 0.035),
respectively (Table 2).
In order to assess whether there is any value in predict-
ing prognosis, the median number of the tumor-associ-
ated immune cells was used as a cut-off point to
dichotomize the 99 patients into a group with a cell num-
ber above the median and a group with a cell number
Table 2: Correlation between the number and microlocalization of immune cells and patient's survival time by a 
univariate analysis
Cell type Islets + Stroma Islets Stroma P (islets 
versus 
stroma)
Number Spearman'
s rho & P
Number Spearman'
s rho & P
Number Spearman'
s rho & P
Macrophages 15.2
(1.8 - 48.4)
rs = -0.105
P = 0.300
4.2
(0.2 - 40.6)
rs = 0.483
P = 0.000
7.2
(0.4 - 39.6)
rs = -0.541
P = 0.000
0.040
Mature 
dendritic cells
13.2
(1.4 - 137.6)
rs = 0.221
P = 0.028
4.2
(0 - 21.4)
rs = 0.404
P = 0.001
7.0
(0.2 - 25.4)
rs = 0.284
P = 0.045
0.000
CD8+ T cells 10.8
(0.4 - 45.0)
rs = 0.297
P = 0.003
4.2
(0 - 66.2)
rs = 0.247
P = 0.014
7.2
(0.2 - 71.4)
rs = 0.212
P = 0.035
0.032
The number of immune cells represents median (range) per high-power field. The number of immune cells in the tumor islets and stroma 
(Islets + Stroma) was obtained by combining the number in the tumor islets and the number in the tumor stroma in each case. Then, the 
numbers of immune cells in the tumor islets and stroma were ranked and the median number was determined. Therefore, the median 
number of immune cells in the tumor islets and stroma is not a simple sum of the median number in the tumor islets and the median number 
in the tumor stroma as shown in this table.
Figure 1 Immunohistochemical detection of tumor-associated immune cells in non-small cell lung cancer tissues. (a) Macrophages (marker 
CD68) stained brown in the tumor islets (arrow) and tumor stroma (arrowhead). (b) Mature dendritic cells (marker CD83) stained brown in the tumor 
islets (arrow) and tumor stroma (arrowhead). (c) Cytotoxic T cells (marker CD8) stained brown in the tumor islets (arrow) and tumor stroma (arrow-
head). Original magnification, × 400.Dai et al. BMC Cancer 2010, 10:220
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below the median. We found that the patients with
above-the-median macrophage number in the tumor
islets and stroma had a similar Kaplan-Meier survival
curve, compared to those patients with below-the-
median macrophage number in the tumor islets and
stroma (P = 0.322, Figure 2a). The patients with above-
the-median macrophage number in the tumor islets had a
significantly better cumulative survival, compared to the
patients with below-the-median macrophage number in
the tumor islets (P = 0.001, Figure 2b). In contrast, the
patients with above-the-median macrophage number in
the tumor stroma had a significantly worse cumulative
survival, compared to the patients with below-the-
median macrophage number in the tumor stroma (P =
0.000, Figure 2c). When the ratio of the macrophage
number in the tumor islets versus the macrophage num-
ber in the tumor stroma was calculated, the patients with
above-the-median ratio (islets/stroma) had a significantly
better cumulative survival, compared to the patients with
below-the-median ratio (P = 0.000, Figure 2d).
The patients with above-the-median numbers of
mature dendritic cells in the tumor islets and stroma,
tumor islets, and tumor stroma had a significantly better
cumulative survival, compared to the patients with
below-the-median numbers of mature dendritic cells (P =
0.000, 0.005, and 0.019, respectively, Figure 3a-c). The
patients with above-the-median ratio (islets/stroma) had
a similar cumulative survival, compared to the patients
with below-the-median ratio (P = 0.099, Figure 3d).
The patients with above-the-median number of cyto-
toxic T cells in the tumor islets and stroma had a signifi-
cantly better cumulative survival, compared to the
patients with below-the-median number of cytotoxic T
cells (P = 0.007, Figure 4a). There were no significant dif-
ferences between the above-the-median and below-the-
median groups, in regard to the number of cytotoxic T
cells in the tumor islets or tumor stroma, or the ratio of
the cell number in the tumor islets versus the cell number
in stroma (P = 0.094, 0.287, and 0.295, respectively, Figure
4b-d).
In order to determine whether the number of tumor-
associated immune cells is correlated to the clinicopatho-
logical characteristics, the number of cases with <
median cell number was compared with the number of
cases with ≥ median cell number. We found that the num-
ber of macrophages was not correlated with the tumor
stage, tumor grade, or lymph node metastasis, except that
the adenocarcinomas had more macrophages in the
tumor islets and stroma, compared to the non-adenocar-
cinomas (i.e., squamous and large cell carcinomas) (P =
0.012) (Table 3). However, there were no significant dif-
ferences when the numbers of macrophages in the tumor
i s l e t s  o n l y  o r  t u m o r  s t r o m a  o n l y  w e r e  c o m p a r e d .  T h e
number of mature dendritic cells was less in the tumors
of advanced stages (III-IV) or with lymph node metasta-
sis, compared to those of early stages (I-II) or without
lymph node metastasis (Table 4). In addition, there were
more mature dendritic cells in the tumor islets and
stroma of the non-adenocarcinomas, compared to the
adenocarcinomas (Table 4). In contrast, the number of
cytotoxic T cells was not correlated with the tumor stage,
histology, or lymph node metastasis, except that the
tumors of poor differentiation had slightly more cytotoxic
T cells in the tumor islets (Table 5).
In order to determine whether the number of tumor-
associated immune cells is independently associated with
patient's survival time, the multivariate Cox proportional
hazards analysis was used. The tumor stage, histology,
grade and lymph node metastasis were included in the
multivariate analysis along with the cell numbers. We
found that only the macrophage numbers in the tumor
islets or tumor stroma were independent predictors of
patient's survival time (P = 0.028 or 0.002, respectively).
The numbers of mature dendritic cells or cytotoxic T
cells were not independent prognostic factors (Table 6).
Figure 2 Kaplan-Meier survival curves demonstrate macrophage number or ratio in correlation to survival. [M] represents the macrophage 
number in the tumor islets and stroma (a), tumor islets (b), and tumor stroma (c). (d) The ratio of the macrophage number in the tumor islets "[M islets]" 
versus the macrophage number in the tumor stroma "[M stroma]".Dai et al. BMC Cancer 2010, 10:220
http://www.biomedcentral.com/1471-2407/10/220
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Discussion
Macrophage is a major component of inflammatory infil-
trate of tumors [8,9]. Studies on the tumor-associated
macrophages (TAMs) in non-small cell lung cancer have
reported controversial results. For example, Chen et al
reported that the TAMs are negatively associated with
survival in the NSCLC patients [10]. Toomey et al found
that there is no association between the macrophage
number and prognosis of NSCLC [11]. On the other
hand, Welsh et al found that the macrophage density in
the tumor islets is positively associated with patient's sur-
vival [12]. Our previous study showed that the mac-
rophage number in the tumor islets is positively
associated with survival, whereas the macrophage num-
ber in the tumor stroma is negatively associated with sur-
vival [6]. In this study, we again confirmed our previous
findings. In addition, we found that the total number of
macrophages in both the tumor islets and stroma does
not predict prognosis. This may be due to the fact that
the macrophage number in the tumor islets is positively
associated with survival, whereas the macrophage num-
ber in the tumor stroma is negatively associated with sur-
vival. Therefore, the positive and negative associations
antagonize each other and reduce the net predictive value
when the two macrophage pools are counted together.
On the other hand, the ratio of macrophage number in
the tumor islets versus the macrophage number in the
tumor stroma appears to better predict the cumulative
survival in the Kaplan-Meier survival curves and univari-
ate analysis (Figure 2d). However, this ratio is not an inde-
pendent predictor of patient's survival in the multivariate
analysis (Table 6). We speculate that this is because some
clinicopathological characteristics may affect the distri-
bution of the ratio and thus its statistic significance in the
multivariate analysis. For example, the overall mac-
rophage number per high-power field was increased in
the adenocarcinomas, which may have an effect on the
predictive value of macrophage ratio in the tumor islets/
stroma. The puzzle of why the macrophages in the tumor
islets are good for prognosis but the macrophages in the
tumor stroma are bad for prognosis may be solved by
investigating microlocalization of the M1 and M2 forms
Figure 3 Kaplan-Meier survival curves demonstrate mature dendritic cell number or ratio in correlation to survival. [D] represents the mature 
dendritic cell number in the tumor islets and stroma (a), tumor islets (b), and tumor stroma (c). (d) The ratio of the mature dendritic cell number in the 
tumor islets "[D islets]" versus the mature dendritic cell number in the tumor stroma "[D stroma]".
Figure 4 Kaplan-Meier survival curves demonstrate cytotoxic T cell number or ratio in correlation to survival. [T] represents the cytotoxic T 
cell number in the tumor islets and stroma (a), tumor islets (b), and tumor stroma (c). (d) The ratio of the cytotoxic T cell number in the tumor islets "[T 
islets]" versus the cytotoxic T cell number in the tumor stroma "[T stroma]".Dai et al. BMC Cancer 2010, 10:220
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Table 3: Correlation between the number of macrophages and clinicopathological characteristics of patients
Variable Islets + Stroma Islets Stroma
< median ≥ median P < median ≥ median P < median ≥ median P
Tumor stage:
I-II 27 28 0.929 24 31 0.228 31 24 0.158
III-IV 22 22 25 19 18 26
Histology
Adenocarcinoma 16 29 0.012 19 26 0.228 19 26 0.228
Non-adenocarcinoma 33 21 30 24 30 24
Tumor grade
Well to moderate 
differentiation
26 24 0.646 26 24 0.248 26 24 0.495
Poor differentiation 14 16 11 19 13 17
Lymph node metastasis
No 28 31 0.624 25 34 0.103 33 26 0.153
Y e s2 1 1 92 4 1 61 6 2 4
of TAMs. The M1 macrophages have anti-tumor func-
tions, whereas the M2 macrophages contain pro-tumor
functions [13,14]. A recent study demonstrated that 70%
of macrophages in the tumor islets are the M1 mac-
rophages in the NSCLC patients with extended survival
[15]. We recently found that about 85% of the mac-
rophages in the tumor stroma are the M2 macrophages in
the NSCLC patients with an average of 1-year survival
(Ma, et al., unpublished observation).
The density of tumor-infiltrating mature dendritic cells
has been found to be a better predictor of clinical out-
come than other parameters in a recent study [16]. Our
results are consistent with this report. The predictive
value of the numbers of mature dendritic cells is only sig-
nificant in the univariate analysis but not in the multivar-
iate analysis. This implies that we need to be cautious in
using the number of mature dendritic cells to predict the
patient's outcome.
T h e  n u m b e r  o f  C D 8 +  T  c e l l s  i n  t h e  t u m o r  i s l e t s  i s
found t o be positive ly associa t ed wit h survival time in
patients with the stage IV NSCLC [17]. Our study shows
the same trend but fails to reach any statistical signifi-
cance (Figure 4b, P = 0.094). We reason that this is
because our patient population (N = 99) is smaller than
that study's patient population (N = 199) [17]. Both stud-
ies showed that the number of cytotoxic T cells in the
tumor stroma is not associated with patient's survival
time. In our study, we found that the total number of
cytotoxic T cells in both the tumor islets and stroma is
positively associated with patient's survival time in the
univariate analysis but not in the multivariate analysis.
This suggests that the clinical significance of counting the
number of cytotoxic T cells is limited, compared to
counting the number of macrophages in the tumor islets
or stroma. The observed differences among the three
immune cells may be caused by the differences in their
biological functions. Macrophages not only can serve as
antigen-presenting cells (like mature dendritic cells), but
also can serve as cytotoxic cells (like cytotoxic T cells)
through releasing reactive oxygen/nitrogen intermediates
and TNFα to kill the nearby tumor cells [18].
In the present study, the 5-year survival rate is 44% for
the patients without lymph node metastasis and 15% for
the patients with lymph node metastasis (Table 1), the
difference of which is very significant (P = 0.002, χ2 analy-
sis). However, it is surprising that the status of lymph
node metastasis is not associated with patient's survival
in a multivariate Cox proportional hazards model analy-
sis (Table 6). Other studies have shown that lymph node
metastasis is an independent prognostic factor in multi-
variate analysis in patients with NSCLC [19,20]. We spec-
ulate that the main reason for this discrepancy is that the
sample size in our series is not big enough to reach statis-
tical significance in the multivariate analysis. This specu-
lation may also be applied to the association of the
density of mature dentritic cells or cytotoxic T cells with
the survival in the multivariate analysis, because it is pos-
sible that these immune parameters would reach statisti-
cal significance in a bigger cohort of patients.
The limitation of this study is that each immune cell
type is identified by a single marker. CD68, CD83 and
CD8 are widely used to identify macrophages, mature
dendritic cells and cytotoxic T cells, respectivelyDai et al. BMC Cancer 2010, 10:220
http://www.biomedcentral.com/1471-2407/10/220
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Table 4: Correlation between the number of mature dendritic cells and clinicopathological characteristics of patients
Variable Islets + Stroma Islets Stroma
< median ≥ median P < median ≥ median P < median ≥ median P
Tumor stage:
I-II 21 34 0.012 23 32 0.107 22 33 0.044
III-IV 28 16 26 18 27 17
Histology
Adenocarcinoma 30 15 0.002 27 18 0.070 27 18 0.070
Non-
adenocarcinoma
19 35 22 32 22 32
Tumor grade
Well to moderate 
differentiation
21 29 0.861 23 27 0.647 26 24 0.066
Poor 
differentiation
12 18 12 18 9 21
Lymph node 
metastasis
No 23 36 0.014 24 35 0.041 25 34 0.103
Yes 26 14 25 15 24 16
Table 5: Correlation between the number of cytotoxic T cells and clinicopathological characteristics of patients
Variable Islets + Stroma Islets Stroma
< median ≥ median P < median ≥ median P < median ≥ median P
Tumor stage:
I-II 23 32 0.107 24 31 0.228 27 28 0.840
III-IV 26 18 25 19 23 21
Histology
Adenocarcinoma 24 21 0.547 23 22 0.841 24 21 0.688
Non-
adenocarcinoma
25 29 26 28 26 28
Tumor grade
Well to moderate 
differentiation
26 24 0.248 29 21 0.040 28 22 0.248
Poor 
differentiation
11 19 10 20 12 18
Lymph node 
metastasis
No 25 34 0.103 27 32 0.416 29 30 0.838
Y e s 2 41 6 2 21 8 2 11 9
[15,17,21-25]. However, these markers are also expressed
by other cell types. For example, CD68 has been found in
immature CD1a-positive dendritic cells [26,27]. CD83 is
also expressed by other cell types such as B lymphocytes
[28]. A better marker for mature dendritic cells is DC-
Lamp (CD208, using rat IgG2a antibodies, clone
SR1010.E1, from Schering-Plough, Kenilworth, NJ) for
paraffin-embedded tissue sections [16]. Although most
tumor-infiltrating CD8+ T cells are cytotoxic T cells [25],
some CD8+ T cells are regulatory T cells [29]. Therefore,
it is possible that a portion of the immune cells identified
by these markers are not the named immune cells (i.e.,Dai et al. BMC Cancer 2010, 10:220
http://www.biomedcentral.com/1471-2407/10/220
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macrophages, mature dendritic cells, and cytotoxic T
cells, respectively).
Conclusions
This study demonstrates that macrophages, mature den-
dritic cells, and cytotoxic T cells are present more in the
tumor stroma than in the tumor islets in non-small cell
lung cancer. Although the number and microlocalization
of the three tumor-associated immune cells appear simi-
lar, the clinical significance of counting these cells is quite
different. The tumor-associated macrophages may be the
most important immune cells in NSCLC, because the
number of TAMs in the tumor islets or stroma can inde-
pendently predict patient's survival time.
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